Article Details

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in ...

Retrieved on: 2024-03-10 20:27:05

Tags for this article:

Click the tags to see associated articles and topics

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in .... View article details on HISWAI: https://www.morningstar.com/news/business-wire/20240310697617/galderma-aad-2024-new-data-demonstrate-the-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-atopic-dermatitis

Summary

Galderma's research on nemolizumab, a monoclonal antibody, shows long-term efficacy in treating prurigo nodularis and atopic dermatitis, with data presented at AAD 2024 underlining its potential in dermatology and epidemiology.

Article found on: www.morningstar.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up